A recombinant FVIII to prevent and control bleeding in people with hemophilia A1
Now available
Novoeight® delivers
the reliability he needs
0
INHIBITORS
CONFIRMED1
One of the largest clinical trials with
no inhibitors confirmed in 213 PTPsa,b
Because he’s always looking ahead, he needs a treatment he can rely on.
Introduce him to Novoeight®, an evolution in treatment that had zero
inhibitors confirmed in PTPs.1,a,b
Malcolm, 18 years old, lives with hemophilia A.
Visit NovoeightPro.com to learn about
additional features and see how Novoeight®
can fit into his world.
PTPs=previously treated patients.
a
Patients with previous inhibitors were excluded from the trial. Individuals with hemophilia A may develop inhibitors to FVII $